Adam N. Mamelak MD

Dr. Mamelak is President and Chief Executive Officer of TLS, as well as a co-inventor of the core technology around which the company was formed. Dr. Mamelak is also a Professor of Neurosurgery at Cedars-Sinai Medical Center in Los Angeles, and an internationally recognized clinician-researcher who has been involved with fluorescence tumor detection and molecular probes for tumor targeting for over 15 years. He has served as a consultant to major medical device companies and has been the principal investigator on numerous NIH, foundation, and industry-supported grants for brain tumor therapy and fluorescence detection. He pioneered the clinical use of radio-iodinated chlorotoxin (CTX) as a tumor-targeting peptide and has served as co-investigator for several CTX trials. Prior to taking over the leadership of TLS, he was a consultant to Transmolecular Industries, Epinano Technologies, and Neurolynx, Inc.

Dr. Mamelak received his medical degree from Harvard Medical School, completed a residency in neurosurgery at UCSF Medical Center, and a post-doctoral research fellowship at California Institute of Technology. He is the former Section Head of Neurosurgery at City of Hope Cancer Center. Dr. Mamelak has published over 100 peer-reviewed articles and has lectured internationally. At TLS, he has successfully negotiated several key financial relationships, including Series A funding, an exclusive license from Cedars Sinai, a contract to develop devices for a molecule company, a collaboration to facilitate device commercialization, and collaboration agreements with several leading microscope and endoscope manufacturers.